

Twinox 200 mg/50 mg chewable tablets for cats and dogs

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:

Twinox 200 mg/50 mg chewable tablets for cats and dogs

Active substance:

Amoxicillin trihydrate

Potassium clavulanate

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin trihydrate

229.61 milligram(s) / 1.00 Tablet

Potassium clavulanate
59.56 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CR02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Italy

Available in:

Italy

Package description:

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 10 tablets. Carton contains 10 tablets.

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 10 tablets. Carton contains 20 tablets.

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 10 tablets. Carton contains 100 tablets.

Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating. Blister contains 10 tablets. Carton contains 500 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

4/04/2022

Manufacturing sites for batch release:

KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:

Ministry Of Health

Authorisation number:

105545

Date of authorisation status change:

4/04/2022

Reference member state:

Ireland

Procedure number:

IE/V/0656/002

Concerned member states:

Austria Belgium France Germany Italy Netherlands Portugal

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics